{"count": 29, "results": [{"_id": "37210012", "pmid": 37210012, "title": "Glucose Metabolism Impairment in Parkinson's Disease.", "journal": "Brain Res Bull", "authors": ["Dai C", "Tan C", "Zhao L", "Liang Y", "Liu G", "Liu H", "Zhong Y", "Liu Z", "Mo L", "Liu X", "Chen L"], "date": "2023-07-01T00:00:00Z", "doi": "10.1016/j.brainresbull.2023.110672", "meta_date_publication": "2023 Jul", "meta_volume": "199", "meta_issue": "", "meta_pages": "110672", "score": 50268.246, "text_hl": "This review discusses the glucose metabolism impairment in @DISEASE_Parkinson_Disease @DISEASE_MESH:D010300 @@@PD@@@ and its pathophysiological mechanisms, and briefly summarized the currently-available therapies targeting @<m>DISEASE_Glucose_Metabolism_Disorders</m> @DISEASE_MESH:D044882 @@@glucose metabolism impairment@@@ in @DISEASE_Parkinson_Disease @DISEASE_MESH:D010300 @@@PD@@@, including @GENE_GLP1R @GENE_2740 @@@glucagon-likepeptide-1 (GLP-1) receptor@@@ agonists and dual @GENE_GLP1R @GENE_2740 @@@GLP-1/gastric inhibitory peptide receptor@@@ agonists, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, and thiazoledinediones.", "citations": {"NLM": "Dai C, Tan C, Zhao L, Liang Y, Liu G, Liu H, Zhong Y, Liu Z, Mo L, Liu X, Chen L. Glucose Metabolism Impairment in Parkinson's Disease. Brain Res Bull. 2023 Jul;199():110672. PMID: 37210012", "BibTeX": "@article{37210012, title={Glucose Metabolism Impairment in Parkinson's Disease.}, author={Dai C and Tan C and Zhao L and Liang Y and Liu G and Liu H and Zhong Y and Liu Z and Mo L and Liu X and Chen L}, journal={Brain Res Bull}, volume={199}, pages={110672}}"}}, {"_id": "35153733", "pmid": 35153733, "pmcid": "PMC8829062", "title": "Deciphering the Roles of Metformin in Alzheimer's Disease: A Snapshot", "journal": "Front Pharmacol", "authors": ["Liao W", "Xu J", "Li B", "Ruan Y", "Li T", "Liu J"], "date": "2022-01-27T00:00:00Z", "doi": "10.3389/fphar.2021.728315", "meta_date_publication": "2021", "meta_volume": "12", "meta_issue": "", "meta_pages": "728315", "score": 50258.39, "text_hl": "Thus, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ treatment could considerably restore the @<m>DISEASE_Glucose_Metabolism_Disorders</m> @DISEASE_MESH:D044882 @@@impaired glucose metabolism@@@ in the brain.", "citations": {"NLM": "Liao W, Xu J, Li B, Ruan Y, Li T, Liu J. Deciphering the Roles of Metformin in Alzheimer's Disease: A Snapshot Front Pharmacol. 2021;12():728315. PMID: 35153733", "BibTeX": "@article{35153733, title={Deciphering the Roles of Metformin in Alzheimer's Disease: A Snapshot}, author={Liao W and Xu J and Li B and Ruan Y and Li T and Liu J}, journal={Front Pharmacol}, volume={12}, pages={728315}}"}}, {"_id": "32017477", "pmid": 32017477, "title": "Non-standard AGE4 epitopes that predict polyneuropathy independently of obesity can be detected by slot dot-blot immunoassay.", "journal": "Adv Clin Exp Med", "authors": ["Bronowicka-Szydełko A", "Krzystek-Korpacka M", "Kuzan A", "Gostomska-Pampuch K", "Gacka M", "Jakobsche-Policht U", "Adamiec R", "Gamian A"], "date": "2020-01-01T00:00:00Z", "doi": "10.17219/acem/112612", "meta_date_publication": "2020 Jan", "meta_volume": "29", "meta_issue": "1", "meta_pages": "91-100", "score": 50237.03, "text_hl": "In @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Glucose_Metabolism_Disorders</m> @DISEASE_MESH:D044882 @@@abnormal glucose metabolism@@@, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ treatment was associated with higher AGE4. ", "citations": {"NLM": "Bronowicka-Szydełko A, Krzystek-Korpacka M, Kuzan A, Gostomska-Pampuch K, Gacka M, Jakobsche-Policht U, Adamiec R, Gamian A. Non-standard AGE4 epitopes that predict polyneuropathy independently of obesity can be detected by slot dot-blot immunoassay. Adv Clin Exp Med. 2020 Jan;29(1):91-100. PMID: 32017477", "BibTeX": "@article{32017477, title={Non-standard AGE4 epitopes that predict polyneuropathy independently of obesity can be detected by slot dot-blot immunoassay.}, author={Bronowicka-Szydełko A and Krzystek-Korpacka M and Kuzan A and Gostomska-Pampuch K and Gacka M and Jakobsche-Policht U and Adamiec R and Gamian A}, journal={Adv Clin Exp Med}, volume={29}, number={1}, pages={91-100}}"}}, {"_id": "39735640", "pmid": 39735640, "title": "Atypical diabetes arising from SHORT syndrome: a case report.", "journal": "Front Endocrinol (Lausanne)", "authors": ["Wang A", "Xu M", "Li L", "Li J"], "date": "2024-12-13T00:00:00Z", "doi": "10.3389/fendo.2024.1467364", "meta_date_publication": "2024", "meta_volume": "15", "meta_issue": "", "meta_pages": "1467364", "score": 50236.996, "text_hl": "Although there are currently no established treatment guidelines for @DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@insulin resistance@@@ in @SPECIES_9606 @@@patients@@@ with @DISEASE_SHORT_syndrome @DISEASE_MESH:C537327 @@@SHORT syndrome@@@, we implemented a comprehensive treatment plan, including lifestyle interventions, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, and @CHEMICAL_voglibose @CHEMICAL_MESH:C102817 @@@voglibose@@@ for @CHEMICAL_Glucose @CHEMICAL_MESH:D005947 @@@glucose@@@ control. ", "citations": {"NLM": "Wang A, Xu M, Li L, Li J. Atypical diabetes arising from SHORT syndrome: a case report. Front Endocrinol (Lausanne). 2024;15():1467364. PMID: 39735640", "BibTeX": "@article{39735640, title={Atypical diabetes arising from SHORT syndrome: a case report.}, author={Wang A and Xu M and Li L and Li J}, journal={Front Endocrinol (Lausanne)}, volume={15}, pages={1467364}}"}}, {"_id": "33759685", "pmid": 33759685, "title": "Hyperthecosis: an underestimated nontumorous cause of hyperandrogenism.", "journal": "Gynecol Endocrinol", "authors": ["Meczekalski B", "Szeliga A", "Maciejewska-Jeske M", "Podfigurna A", "Cornetti P", "Bala G", "Adashi EY"], "date": "2021-08-01T00:00:00Z", "doi": "10.1080/09513590.2021.1903419", "meta_date_publication": "2021 Aug", "meta_volume": "37", "meta_issue": "8", "meta_pages": "677-682", "score": 50234.348, "text_hl": "In @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Glucose_Metabolism_Disorders</m> @DISEASE_MESH:D044882 @@@impaired glucose metabolism@@@ and @DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@insulin resistance@@@, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ should also be considered as part of treatment. ", "citations": {"NLM": "Meczekalski B, Szeliga A, Maciejewska-Jeske M, Podfigurna A, Cornetti P, Bala G, Adashi EY. Hyperthecosis: an underestimated nontumorous cause of hyperandrogenism. Gynecol Endocrinol. 2021 Aug;37(8):677-682. PMID: 33759685", "BibTeX": "@article{33759685, title={Hyperthecosis: an underestimated nontumorous cause of hyperandrogenism.}, author={Meczekalski B and Szeliga A and Maciejewska-Jeske M and Podfigurna A and Cornetti P and Bala G and Adashi EY}, journal={Gynecol Endocrinol}, volume={37}, number={8}, pages={677-682}}"}}, {"_id": "31313243", "pmid": 31313243, "pmcid": "PMC6952330", "title": "The treatment with pasireotide in Cushing's disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center", "journal": "J Endocrinol Invest", "authors": ["Simeoli C", "Ferrigno R", "De Martino MC", "Iacuaniello D", "Papa F", "Angellotti D", "Pivonello C", "Patalano R", "Negri M", "Colao A", "Pivonello R"], "date": "2020-01-01T00:00:00Z", "doi": "10.1007/s40618-019-01077-8", "meta_date_publication": "2020 Jan", "meta_volume": "43", "meta_issue": "1", "meta_pages": "57-73", "score": 50228.32, "text_hl": "cAntidiabetic drugs: @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, short-acting @GENE_INS @GENE_3630 @@@insulin@@@, long-acting insulin", "citations": {"NLM": "Simeoli C, Ferrigno R, De Martino MC, Iacuaniello D, Papa F, Angellotti D, Pivonello C, Patalano R, Negri M, Colao A, Pivonello R. The treatment with pasireotide in Cushing's disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center J Endocrinol Invest. 2020 Jan;43(1):57-73. PMID: 31313243", "BibTeX": "@article{31313243, title={The treatment with pasireotide in Cushing's disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center}, author={Simeoli C and Ferrigno R and De Martino MC and Iacuaniello D and Papa F and Angellotti D and Pivonello C and Patalano R and Negri M and Colao A and Pivonello R}, journal={J Endocrinol Invest}, volume={43}, number={1}, pages={57-73}}"}}, {"_id": "20155995", "pmid": 20155995, "title": "Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions.", "journal": "CNS Drugs", "authors": ["Hasnain M", "Vieweg WV", "Fredrickson SK"], "date": "2010-03-01T00:00:00Z", "doi": "10.2165/11530130-000000000-00000", "meta_date_publication": "2010 Mar", "meta_volume": "24", "meta_issue": "3", "meta_pages": "193-206", "score": 50067.016, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ for atypical antipsychotic-induced @DISEASE_Weight_Gain @DISEASE_MESH:D015430 @@@weight gain@@@ and @<m>DISEASE_Glucose_Metabolism_Disorders</m> @DISEASE_MESH:D044882 @@@glucose metabolism dysregulation@@@: review of the literature and clinical suggestions.", "citations": {"NLM": "Hasnain M, Vieweg WV, Fredrickson SK. Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions. CNS Drugs. 2010 Mar;24(3):193-206. PMID: 20155995", "BibTeX": "@article{20155995, title={Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions.}, author={Hasnain M and Vieweg WV and Fredrickson SK}, journal={CNS Drugs}, volume={24}, number={3}, pages={193-206}}"}}, {"_id": "28335557", "pmid": 28335557, "pmcid": "PMC5372684", "title": "ROS Production and ERK Activity Are Involved in the Effects of d-beta-Hydroxybutyrate and Metformin in a Glucose Deficient Condition", "journal": "Int J Mol Sci", "authors": ["Lamichhane S", "Bastola T", "Pariyar R", "Lee ES", "Lee HS", "Lee DH", "Seo J"], "date": "2017-03-21T00:00:00Z", "doi": "10.3390/ijms18030674", "meta_date_publication": "2017 Mar 21", "meta_volume": "18", "meta_issue": "3", "meta_pages": "", "score": 50062.035, "text_hl": "The cytotoxic mechanism of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ under @<m>DISEASE_Glucose_Metabolism_Disorders</m> @DISEASE_MESH:D044882 @@@glucose deficiency@@@ was also examined. ", "citations": {"NLM": "Lamichhane S, Bastola T, Pariyar R, Lee ES, Lee HS, Lee DH, Seo J. ROS Production and ERK Activity Are Involved in the Effects of d-beta-Hydroxybutyrate and Metformin in a Glucose Deficient Condition Int J Mol Sci. 2017 Mar 21;18(3):. PMID: 28335557", "BibTeX": "@article{28335557, title={ROS Production and ERK Activity Are Involved in the Effects of d-beta-Hydroxybutyrate and Metformin in a Glucose Deficient Condition}, author={Lamichhane S and Bastola T and Pariyar R and Lee ES and Lee HS and Lee DH and Seo J}, journal={Int J Mol Sci}, volume={18}, number={3}}"}}, {"_id": "21564529", "pmid": 21564529, "title": "Should metformin be our antiglycemic agent of choice post-transplantation?", "journal": "Am J Transplant", "authors": ["Sharif A"], "date": "2011-07-01T00:00:00Z", "doi": "10.1111/j.1600-6143.2011.03550.x", "meta_date_publication": "2011 Jul", "meta_volume": "11", "meta_issue": "7", "meta_pages": "1376-81", "score": 50060.562, "text_hl": "Should @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ be our antiglycemic agent of choice post-transplantation?", "citations": {"NLM": "Sharif A. Should metformin be our antiglycemic agent of choice post-transplantation? Am J Transplant. 2011 Jul;11(7):1376-81. PMID: 21564529", "BibTeX": "@article{21564529, title={Should metformin be our antiglycemic agent of choice post-transplantation?}, author={Sharif A}, journal={Am J Transplant}, volume={11}, number={7}, pages={1376-81}}"}}, {"_id": "30034573", "pmid": 30034573, "pmcid": "PMC6035806", "title": "mTOR Inhibitor Therapy and Metabolic Consequences: Where Do We Stand?", "journal": "Oxid Med Cell Longev", "authors": ["Kezic A", "Popovic L", "Lalic K"], "date": "2018-06-24T00:00:00Z", "doi": "10.1155/2018/2640342", "meta_date_publication": "2018", "meta_volume": "2018", "meta_issue": "", "meta_pages": "2640342", "score": 50058.836, "text_hl": "Here, we review the recent advances in our understanding of the metabolic consequences regarding @CHEMICAL_Glucose @CHEMICAL_MESH:D005947 @@@glucose@@@ metabolism induced by @GENE_MTOR @GENE_2475 @@@mTOR@@@ inhibitors and compare them to the metabolic profile provoked by @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ use. We further suggest @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ use concurrent with rapalogs in order to pharmacologically address the @<m>DISEASE_Glucose_Metabolism_Disorders</m> @DISEASE_MESH:D044882 @@@impaired glucose metabolism@@@ and prevent the development of new-onset @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes mellitus@@@ after solid organ transplantations induced by the chronic rapalog treatment.", "citations": {"NLM": "Kezic A, Popovic L, Lalic K. mTOR Inhibitor Therapy and Metabolic Consequences: Where Do We Stand? Oxid Med Cell Longev. 2018;2018():2640342. PMID: 30034573", "BibTeX": "@article{30034573, title={mTOR Inhibitor Therapy and Metabolic Consequences: Where Do We Stand?}, author={Kezic A and Popovic L and Lalic K}, journal={Oxid Med Cell Longev}, volume={2018}, pages={2640342}}"}}]}